0001209191-20-024476.txt : 20200415
0001209191-20-024476.hdr.sgml : 20200415
20200415161524
ACCESSION NUMBER: 0001209191-20-024476
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200413
FILED AS OF DATE: 20200415
DATE AS OF CHANGE: 20200415
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Silva Paul M
CENTRAL INDEX KEY: 0001446372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20793853
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-13
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001446372
Silva Paul M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
SVP & Controller
Common Stock
2020-04-13
4
M
0
859
90.29
A
15791
D
Common Stock
2020-04-13
4
S
0
50
244.09
D
15741
D
Common Stock
2020-04-13
4
S
0
150
245.62
D
15591
D
Common Stock
2020-04-13
4
S
0
150
247.18
D
15441
D
Common Stock
2020-04-13
4
S
0
150
248.96
D
15291
D
Common Stock
2020-04-13
4
S
0
193
250.29
D
15098
D
Common Stock
2020-04-13
4
S
0
166
252.26
D
14932
D
Common Stock
169
I
401(k)
Stock Option (Right to Buy)
90.29
2020-04-13
4
M
0
859
0.00
D
2026-07-11
Common Stock
859
860
D
Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $245.62 (range $245.31 to $246.00).
Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $247.18 (range $246.88 to $247.44).
Open market sales reported on this line occurred at a weighted average price of $248.96 (range $248.75 to $249.30).
Open market sales reported on this line occurred at a weighted average price of $250.29 (range $249.95 to $250.54).
Open market sales reported on this line occurred at a weighted average price of $252.26 (range $251.99 to $252.85).
The option vests in 16 quarterly installments from 07/12/2016.
Omar White, Attorney-in-Fact
2020-04-15